PERTH-BASED biotechnology player Rockeby Biomed is one step away from receiving a US patent covering the intellectual property of its point-of-care rapid diagnostic test, Candia5.
When awarded, the patent will cover all jurisdictions under the US Patents and Trade Marks office.
The Candia5 test kit for the diagnosis of thrush is a non-invasive test and is marketed as a point-of-care test kit for general practitioners, pharmacists, obstetricians and gynaecologists.
Rockeby is also in the final stages of completing a Food and Drug Administration trial in the US. That is due by the end of the year.